Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
AbbVie Inc on Wednesday raised its annual guidance reflecting confidence in its long-term outlook after a quarter of ...
AbbVie Inc on Thursday said earnings in the last quarter slumped despite compelling revenue growth across the busines ...
A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to ...
A number of leading pharmaceutical companies on Monday reported positive trial results on the treatment of lymphoma, ...
AbbVie Inc on Thursday said Ubrelvy reduces the headache phase of a migraine attack. The North Chicago, Illinois-bas ...
AbbVie Inc on Friday reported a decline in third-quarter revenue and a profit decline, though it lifted bottom line g ...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
V C FORM 8.3 - Amendment to Purchase and Sales IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN...
V H C Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
